UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference. The company's management team is scheduled to present on Monday, March 10, 2025, at 4:20pm ET (1:20pm PT) in Miami, FL.
The presentation will be available through a live webcast, with a replay accessible for two weeks afterward through the Events section of NeuroPace's Investor website. Additionally, the management team will be conducting investor meetings throughout the conference.
Details
News Market Reaction – NPCE
The recorded move for NPCE in the trading session of this news was +0.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference.
The presentation will be accessible via live webcast here. A webcast replay will be available for two weeks following the presentation in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.